Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Biomédica (Bogotá) ; 34(3): 387-402, July-Sept. 2014. ilus
Article in Spanish | LILACS | ID: lil-726799

ABSTRACT

Introducción. El factor de transcripción asociado a la microftalmia ( Microphtalmia-Associated Transcription Factor , MITF) regula la expresión de genes específicos, pero no se conoce su expresión y su función a nivel cardiaco. Objetivos. Identificar la expresión del MITF en corazón y en cardiomiocitos aislados de cobayo, describir los cambios morfológicos asociados con su disminución y evaluar los niveles relativos de su expresión en cardiomiocitos aislados en condiciones de preacondicionamiento isquémico. Materiales y métodos. El análisis de la expresión relativa de la isoforma específica de tejido cardiaco ( heart-type MITF, MITF-H), se determinó mediante reacción en cadena de la polimerasa (PCR) en tiempo real semicuantitativa, secuenciación y Western blot . La disminución del ARNm del MITF se indujo con un ARN pequeño de interferencia ( short hairpin RNA interference , shRNAi) específico. El tamaño, el diámetro y el número de fibras musculares se evaluaron por observación directa con microscopía de luz. Resultados. Se amplificó un fragmento de 281 pb de ADNc; el análisis de la secuencia confirmó la identidad del exón 1 y la isoforma H del MITF. La interferencia del ARNm del MITF se asoció con un mayor índice cardiaco (peso corazón/peso corporal: 5,46 x 10 -3 Vs. 4,6 x 10 -3 ) y un incremento del diámetro de las fibras cardiacas (50,2±16 µm Vs. 38,7±14,7 µm; p<0,05, n=150). En los cardiomiocitos aislados en condiciones de preacondicionamiento isquémico, se observó una expresión relativa del MITF-H mayor que en los miocitos en normoxia y expuestos a lesión por isquemia simulada (80 y 100 veces más, n=5, p<0,05, n=3). Conclusión. Los resultados sugieren que el MITF-H podría estar involucrado en la hipertrofia, la respuesta al estrés por isquemia y la supervivencia de cardiomiocitos de cobayo.


Introduction: The microphthalmia -associated transcription factor ( MITF ) regulates the expression of specific genes and its cardiac expression and function is not known. Objectives: To identify the expression of MITF in hearts and isolated cardiomyocytes from Guinea pigs, to describe morphological changes associated with mRNA interference of MITF and to evaluate their relative changes in expression in isolated cardiomyocytes under ischemic preconditioning. Materials and methods: The cardiac specific isoform, MITF-H, and relative expression level analysis, was determined by semi-quantitative real time PCR, sequencing and Western blotting. Reduction of mRNA-MITF-H was induced by transduction of specific-MITF-shRNAi interference. The cardiac morphological changes, diameter and number of cardiac fibers were evaluated by direct observation and light microscopy. Results: A cDNA fragment of 281 bp was amplified from heart and isolated ventricular cardiac myocytes. Sequence analysis confirmed the identity of the isoform MITF-H, exon 1. The MITF silencing was associated with an increase in cardiac index (heart weight/body weight vs . 5.46 x 10 -3 vs 4.6 x 10 -3 ) and higher diameter of cardiac fibers (50.2±16 µ m vs 38,7±14,7 µ m p<0.05, n=150). In isolated cardiac myocytes under ischemic preconditioning we observed a higher relative expression compared with that measured in myocytes exposed to normoxia and simulated ischemia (eighty and one hundred times, p <0.05, n = 5). Conclusion. The results suggest that MITF-H isoform may be involved in Guinea pig cardiac hypertrophy, response to stress by ischemia and cardiomyocytes survival.


Subject(s)
Animals , Female , Guinea Pigs , Cardiomyopathy, Hypertrophic/metabolism , Microphthalmia-Associated Transcription Factor/physiology , Myocardium/metabolism , Myocytes, Cardiac/metabolism , Amino Acid Sequence , Base Sequence , Cell Survival , Cells, Cultured , Cardiomyopathy, Hypertrophic/genetics , DNA, Complementary/genetics , Gene Expression Regulation , Ischemic Preconditioning, Myocardial , Molecular Sequence Data , Microphthalmia-Associated Transcription Factor/antagonists & inhibitors , Microphthalmia-Associated Transcription Factor/biosynthesis , Microphthalmia-Associated Transcription Factor/genetics , Myocardial Ischemia/genetics , Myocardial Ischemia/metabolism , Myocytes, Cardiac/pathology , Oxygen/pharmacology , Protein Isoforms/biosynthesis , Protein Isoforms/genetics , Protein Isoforms/physiology , RNA Interference , RNA, Small Interfering/pharmacology , Sequence Alignment , Sequence Homology
2.
Arq. bras. cardiol ; 96(4): 332-339, abr. 2011. ilus, tab
Article in Portuguese | LILACS | ID: lil-585905

ABSTRACT

A titina é uma proteína sarcomérica gigante que se estende desde a linha Z até a linha M. Em razão de sua localização, representa um importante sensor biomecânico com um papel fundamental na manutenção da integridade estrutural do sarcômero. A titina funciona como uma "mola bidirecional" que regula o comprimento sarcomérico e realiza ajustes adequados da tensão passiva sempre que o comprimento varia. Dessa forma, não só determina a rigidez ventricular e a função diastólica, como também influencia a função cardíaca sistólica, modulando o mecanismo de Frank-Starling. O miocárdio expressa duas isoformas dessa macromolécula: a N2B, mais rígida, e a isoforma N2BA, mais complacente. As alterações na expressão relativa das duas isoformas da titina ou alterações do seu estado de fosforilação têm sido implicadas na fisiopatologia de várias doenças como a insuficiência cardíaca diastólica, a cardiomiopatia dilatada, a cardiomiopatia isquêmica e a estenose aórtica. Neste artigo pretende-se descrever sumariamente a estrutura e localização da titina, a sua relação com diferentes cardiomiopatias, e compreender de que forma as alterações dessa macromolécula influenciam a fisiopatologia da insuficiência cardíaca diastólica, salientando o potencial terapêutico da manipulação dessa macromolécula.


Titin is a giant sarcomeric protein that extends from the Z-line to the M-line. Due to its location, it represents an important biomechanical sensor, which has a crucial role in the maintenance of the sarcomere structural integrity. Titin works as a "bidireactional spring" that regulates the sarcomeric length and performs adequate adjustments of passive tension whenever the length varies. Therefore, it determines not only ventricular rigidity and diastolic function, but also systolic cardiac function, modulating the Frank-Starling mechanism. The myocardium expresses two isoforms of this macromolecule: the N2B, more rigid and the isoform N2BA, more compliant. The alterations in the relative expression of the two titin isoforms or alterations in their state of phosphorylation have been implicated in the pathophysiology of several diseases, such as diastolic heart failure, dilated cardiomyopathy, ischemic cardiomyopathy and aortic stenosis. The aim of this study is to describe, in brief, the structure and location of titin, its association with different cardiomyopathies and understand how alterations in this macromolecule influence the pathophysiology of diastolic heart failure, emphasizing the therapeutic potential of the manipulation of this macromolecule.


La titina es una proteína sarcomérica gigante que se extiende desde la línea Z hasta la línea M. En razón de su ubicación, representa un importante sensor biomecánico con un papel fundamental en la manutención de la integridad estructural del sarcómero. La titina funciona como un "resorte bidireccional" que regula el largo sarcomérico y realiza ajustes adecuados de la tensión pasiva siempre que ese largo varía. De esa forma, no sólo determina la rigidez ventricular y la función diastólica, sino también influye en la función cardíaca sistólica, modulando el mecanismo de Frank-Starling. El miocardio expresa dos isoformas de esa macromolécula: la N2B, más rígida, y la isoforma N2BA, más complaciente. Las alteraciones en la expresión relativa de las dos isoformas de la titina o alteraciones de su estado de fosforilación han sido implicadas en la fisiopatología de varias enfermedades como la insuficiencia cardíaca diastólica, la cardiomiopatía dilatada, la cardiomiopatía isquémica y la estenosis aórtica. Este artículo pretende describir sumariamente la estructura y ubicación de la titina, su relación con diferentes cardiomiopatías, y comprender de qué forma las alteraciones de esa macromolécula influyen en la fisiopatología de la insuficiencia cardíaca diastólica, destacando el potencial terapéutico de la manipulación de esa macromolécula.


Subject(s)
Humans , Heart Failure/physiopathology , Muscle Proteins/physiology , Protein Kinases/physiology , Sarcomeres/chemistry , Cardiomyopathies/physiopathology , Muscle Proteins/chemistry , Myocardium/chemistry , Protein Isoforms/chemistry , Protein Isoforms/physiology , Protein Kinases/chemistry
3.
Braz. j. morphol. sci ; 23(2): 187-194, Apr.-June 2006. tab, ilus
Article in English | LILACS | ID: lil-468070

ABSTRACT

It is now generally accepted that hybrid skeletal muscle fibres are not experimental artefacts, but complex molecular systems that expand the functional repertoire of the muscle to which they belong. The purpose of this review is to highlight the cognitive value of hybrid fibres by discussing several insights into skeletal muscle biology produced by studies using hybrid fibres and/or muscles containing hybrid fibres. There is strong evidence that hybrid fibres can be used as indicators of muscle remodeling and specialization. Also, there is increasing evidence that hybrid fibres are suitable for investigating issues related to (i) the coexpression of different myosin heavy chain (MHC) isoforms and their assembly in the sarcomeric structure, (ii) the operation of the muscle cell as a multinuclear system, (iii) the tightness of the relationship between MHC isoform expression and expression of other polymorphic muscle proteins, (iv) the tightness of the relationship between MHC isoform expression and various contractile parameters, and (v) the extent of the neural input into defining the molecular and functional phenotype of skeletal muscle cells. It is predicted that, when used together with imaginatively designed methods, the hybrid fibres will further our (still limited) understanding of the regulation of muscle gene expression in multinuclear cells and of the interactions of gene products within and across different intracellular signalling pathways.


Subject(s)
Denervation , Protein Isoforms/physiology , Myosin Heavy Chains , Myosins , Muscle, Skeletal/physiology , Polymorphism, Genetic , Muscle Proteins/metabolism , Troponin C , Myosin Heavy Chains/biosynthesis , Protein Isoforms/chemistry , Muscle, Skeletal/blood supply , Skeletal Muscle Myosins
4.
Biol. Res ; 37(4): 583-591, 2004. ilus, tab, graf
Article in English | LILACS | ID: lil-437512

ABSTRACT

Here we compare excitation-contraction coupling in single muscle cells of frogs and rats. Because amphibians have isoform 3 (or b) of the ryanodine receptor/Ca2+ release channel, in addition to 1 (a), which is also present in the mammal, any extra feature present in the frog may in principle be attributed to isoform 3. Ca2+ release under voltage clamp depolarization has a peak and a steady phase in both taxonomic classes, but the peak is more marked in the frog, where the ratio of amplitudes of the two phases is voltage-dependent. This dependence is a hallmark of CICR. Confocal imaging identified Ca2+ sparks in the frog, but not in the voltage-clamped rat cells. Because Ca2+ sparks involve CICR both observations indicate that the contribution of CICR is minor or null in the mammal. The "couplon" model well accounts for observations in the frog, but assumes a structure that we now know to be valid only for the rat. A revised model is proposed, whereby the isoform 3 channels, located parajunctionally, are activated by CICR and contribute its characteristic global and local features. Several issues regarding the roles of different channels remain open to further study.


Subject(s)
Animals , Rats , Calcium/metabolism , Ryanodine Receptor Calcium Release Channel/physiology , Ryanodine Receptor Calcium Release Channel/metabolism , Muscle Contraction/physiology , Sarcoplasmic Reticulum/physiology , Anura , Protein Isoforms/physiology , Models, Biological , Membrane Potentials/physiology , Species Specificity , Calcium Signaling/physiology
5.
Rev. invest. clín ; 54(4): 349-356, jul.-ago. 2002.
Article in Spanish | LILACS | ID: lil-332903

ABSTRACT

El desarrollo de mecanismos para evadir la acción de los fármacos y desarrollar resistencia a los mismos es un evento universal en los organismos vivos. Se presenta en virus, bacterias, hongos, plantas y animales. En una población de seres vivos algunos individuos son capaces de encender genes apagados, de mutar la secuencia de otros genes, de sintetizar nuevas moléculas para desarrollar los mecanismos que les permiten sobrevivir y perpetuar la especie en circunstancias adversas. La acumulación de eventos de adaptación y mutagénesis pueden dar lugar a la aparición de organismos con características diferentes a la mayoría de los individuos de su especie, las cuales al acumularse podrían constituir nuevas especies. De manera que los cambios para la adaptación y la sobrevivencia de los individuos constituyen en última instancia las bases de la evolución. Uno de los mecanismos que las células han desarrollado para sobrevivir en presencia de sustancias tóxicas es el llamado fenotipo de resistencia a múltiples drogas o MDR (por sus siglas en inglés, multidrug resistance). Este evento se caracteriza porque las células presentan resistencia a drogas con estructuras químicas y blancos de acción distintos. El fenotipo de MDR se descubrió primeramente en células transformadas de mamífero, las cuales expresan una glicoproteína de aproximadamente 170 kDa en su superficie, denominada Pgp. Posteriormente este mecanismo se ha descubierto en muchas especies, incluyendo a los protozoarios parásitos...


Subject(s)
Animals , Entamoeba histolytica , Antiprotozoal Agents , Drug Resistance, Multiple , Phenotype , Promoter Regions, Genetic , Cloning, Molecular , Genes, Protozoan , Genes, MDR , Emetine , Entamoeba histolytica , Gene Amplification , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/physiology , Protein Isoforms/genetics , Protein Isoforms/physiology , Protozoan Proteins/genetics , Protozoan Proteins/physiology , Transcription, Genetic
6.
Rev. invest. clín ; 54(2): 145-153, Mar.-Abr. 2002.
Article in Spanish | LILACS | ID: lil-332934

ABSTRACT

Cholesterol is an important lipid in higher organisms, and its concentration must be maintained in narrow limits depending of the cell needs. An excess of dietary cholesterol can lead to serious health problems, however, if consumption of this lipid is restricted in the diet, cells have the capacity to synthesize it. For the synthesis of cholesterol, the cell uses a family of proteins named sterol regulatory element binding proteins (SREBP's), that are transcriptional factors involved in the control of expression of genes of cholesterol and fatty acids synthesis. SREBP's regulate gene transcription by binding to cis-acting elements denominated sterol regulatory elements (SRE-1). SREBP's are localized in the endoplasmic reticulum, but in the event that the cell needs to synthesize cholesterol, the NH2-terminal portion of these proteins is cleaved by two specific proteases, and then travels into the nucleus to function as transcriptional factor. The present review shows the details of the mechanism that the cell uses to regulate cholesterol biosynthesis by the SREBP's, and its potential metabolic implications.


Subject(s)
Humans , Animals , Cricetinae , Mice , Cholesterol , DNA-Binding Proteins , Fatty Acids/biosynthesis , Transcription Factors/physiology , CCAAT-Enhancer-Binding Proteins/physiology , Gene Expression Regulation/physiology , Cholesterol, Dietary , DNA-Binding Proteins , Genes , Insulin , Mice, Mutant Strains , Transcription Factors/genetics , Protein Isoforms/physiology , Membrane Proteins/physiology , CCAAT-Enhancer-Binding Proteins/genetics , Regulatory Sequences, Nucleic Acid
7.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 11(4): 751-761, jul.-ago. 2001. tab
Article in Portuguese | LILACS, SES-SP | ID: lil-394923

ABSTRACT

O tratamento atual da síndrome coronariana aguda requer decisões rápidas. Os pacientes devem ser triados rápida e adequadamente, e liberados precocemente e com segurança. Os critérios diagnósticos de infarto agudo do miocárdio foram estabelecidos pela Organização Mundial da Saúde, pela presença de dois dos seguintes critérios: história e dor característica para isquemia, alterações eletrocardiográficas típicas, e elevação e normalização das enzimas cardíacas. Nos últimos trinta anos, a isoenzima CK-MB atividade tem sido o marcador padrão para esse diagnóstico, embora não seja específico para o diagnóstico. Novos métodos automatizados com testes imunológicos que utilizam anticorpos monoclonais para CK-MB massa, isoformas da CK-MB, mioglobina e troponina I e T foram introduzidos como possíveis substitutos da CK-MB atividade. Esses novos marcadores são mais sensíveis e específicos e podem detectar a presença de lesões mínimas do miocárdio em pacientes com dor torácica. Estudos recentes, que avaliaram o prognóstico desses pacientes, demonstraram que os portadores de troponina positiva evoluem com risco maior de óbito a curto e médio prazos. O uso desses marcadores pode, também, identificar a terapia mais adequada para essa população. A utilização da razão pré e pós-terapia fibrinolítica é um método eficaz para diagnóstico de reperfusão miocárdica. Este artigo examinará o papel das enzimas e proteínas cardíacas no diagnóstico bioquímico do infarto agudo do miocárdio, seu valor prognóstico, incluindo a creatina cinase, suas isoenzimas e isoformas, a desidrogenase láctica, a mioglobina e as troponinas T e I.


Subject(s)
Humans , Adult , Aged , Creatine Kinase , Isoenzymes , Myocardial Infarction/diagnosis , Protein Isoforms/physiology , Protein Isoforms/history , Protein Isoforms , Oxidoreductases , Troponin , Diabetes Mellitus , Myoglobin , Biomarkers , Myocardial Reperfusion
8.
Rev. invest. clín ; 52(6): 686-91, nov.-dic. 2000. ilus, tab, CD-ROM
Article in Spanish | LILACS | ID: lil-295057

ABSTRACT

La progesterona participa en la regulación de diversos procesos fisiológicos en los mamíferos. La respuesta biológica a la progesterona está mediada por dos isoformas del receptor a progesterona (PR) denominadas PR-A y PR-B. La diferencia entre éstas está dada por 164 aminoácidos de la región amino-terminal de PR-B que están ausentes en PR-A. Ambas isoformas son codificadas por el mismo gen pero son reguladas por distintos promotores que son inducidos por los estrógenos. PR-B actúa como un fuerte activador transcripcional en diferentes contextos celulares mientras que PR-A funciona como un inhibidor. El contenido de las isoformas del PR, así como su regulación por hormonas esteroides se presenta de manera tejido-específica en los órganos blanco como el útero, la glándula mamaria y el cerebro. El conocimiento de los mecanismos moleculares por los cuales se regula la expresión y función de las isoformas del PR permitirá entender procesos biológicos fundamentales como la conducta sexual y la reproducción; además contribuirá al diseño de terapias hormonales en el control de la fertilidad, así como en el tratamiento de tumores de mama, endometriales y cerebrales.


Subject(s)
Estradiol , Protein Isoforms/physiology , Progesterone/physiology , Neoplasms/drug therapy , Steroids/physiology
SELECTION OF CITATIONS
SEARCH DETAIL